Bright Minds Biosciences (DRUG) Cash & Equivalents (2019 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Cash & Equivalents data on file, last reported at $225.8 million in Q1 2026.

• Quarterly Cash & Equivalents rose 481.97% year-over-year to $225.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $225.8 million (up 481.97% YoY) and the FY2025 annual result came in at $60.2 million, up 1336.74% from the prior year.
• Cash & Equivalents climbed to $225.8 million in Q1 2026, from $63.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $225.8 million in Q1 2026 to a low of $4.2 million in Q3 2024.
• A 5-year average of $31.6 million and a median of $8.3 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 62.14% — and 2025, when it surged 1336.74%.
• Tracing DRUG's Cash & Equivalents over 5 years: stood at $8.3 million in 2022, then plunged by 39.87% to $5.0 million in 2023, then soared by 734.47% to $41.4 million in 2024, then soared by 54.07% to $63.9 million in 2025, then surged by 253.66% to $225.8 million in 2026.
• The last three Cash & Equivalents figures came in at $225.8 million (Q1 2026), $63.9 million (Q4 2025), and $60.2 million (Q3 2025), per Business Quant data.